| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| HGR-HF224 | Human | FITC-Labeled Human HGF R / c-MET Protein, His Tag |  |
|
|
| MET-C5256 | Canine | Canine HGF R / c-MET Protein,Fc Tag (MALS verified) |  |
|
|
| MET-R5256 | Rhesus macaque | Rhesus macaque HGF R / c-MET Protein,Fc Tag |  |
|
|
| MET-M5254 | Mouse | Mouse HGF R / c-MET Protein, Fc Tag (MALS verified) |  |
|
|
| MBS-K021 | Human | Human HGF R-coupled Magnetic Beads |
|
||
| MET-H82E1 | Human | Biotinylated Human HGF R / c-MET Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| MET-H5256 | Human | Human HGF R / c-MET Protein, Fc Tag (MALS verified) |  |
|
|
| MET-H5227 | Human | Human HGF R / c-MET Protein, His Tag |  |
|
|
Immobilized Canine HGF R,Fc Tag (Cat. No. MET-C5256) at 5 μg/mL (100 μL/well) can bind Human HGF, His Tag (Cat. No. HGF-H52H3) with a linear range of 2-16 ng/mL (QC tested).
The purity of Canine HGF R,Fc Tag (Cat. No. MET-C5256) is more than 90% and the molecular weight of this protein is around 290-320 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ensartinib Hydrochloride | X-396 | Approved | Xcovery | 贝美纳 | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2020-11-17 | Solid tumours; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
| Savolitinib | HMP-504; HMPL-504; HM-5016504; AZD-6094 | Approved | Hutchison Medipharma Ltd | 沃瑞沙, ORPATHYS | Mainland China | Carcinoma, Non-Small-Cell Lung | Hutchison Huangpu Medicine (Shanghai) Co Ltd | 2021-06-22 | Kidney Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Kidney Diseases; Neoplasms; Urologic Neoplasms; Lung Neoplasms; Carcinosarcoma; Carcinoma, Non-Small-Cell Lung | Details |
| Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pain; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Capmatinib Hydrochloride | NVP-INC280-NX; INCB-28060; C2A374O70X; INC-280; INCB-028060 | Approved | Incyte Corp, Novartis Pharma Ag | Tabrecta | Japan | Carcinoma, Non-Small-Cell Lung | Novartis Pharma Ag | 2020-05-06 | Liver Neoplasms; Solid tumours; Carcinoma; Adenocarcinoma of Lung; Triple Negative Breast Neoplasms; Hepatic Insufficiency; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
| Amivantamab | JNJ-372; JNJ-61186372 | Approved | Janssen Global Services Llc, Genmab | RYBREVANT | EU | Carcinoma, Non-Small-Cell Lung | Janssen-Cilag International Nv | 2021-05-21 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Pharmaceuticals Ltd (China) | 赛可瑞, Xalkori | United States | Lymphoma, Large-Cell, Anaplastic | Pf Prism Cv | 2011-08-26 | Kidney Diseases; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung | Details |
| Tepotinib hydrochloride hydrate | EMD-1214063; MSC-2156119; MSC-2156119J | Approved | Merck Serono | テプミトコ, TEPMETKO, Tepmetko | United States | Carcinoma, Non-Small-Cell Lung | Emd Serono Inc | 2020-03-25 | Solid tumours; Hepatic Insufficiency; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SAIT-301 | SAIT-301 | Phase 1 Clinical | Samung Medical Centre | Neoplasms | Details |
| Emibetuzumab | LA-480; LY-2875358 | Phase 2 Clinical | Eli Lilly And Company | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| Glumetinib | SCC244; HH-SCC244 | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Greenvalley Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| ASLAN-002 | ASLAN-002; BMS-777607; BMS-797669 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| MCLA-129 | MCLA-129 | Phase 2 Clinical | Merus | Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms | Details |
| Glesatinib | MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly | Phase 2 Clinical | Mirati Therapeutics | Carcinoma, Non-Small-Cell Lung | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Biliary Tract Neoplasms; Skin Melanoma; Pancreatic Neoplasms; Microsatellite instability-high cancer; Cholangiocarcinoma; Breast Neoplasms; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Gallbladder Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis | Details |
| SAR-125844 | SAR-125844 | Phase 2 Clinical | Sanofi | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CBT-101 | CBT-101 | Phase 1 Clinical | Crown Bioscience | Solid tumours | Details |
| AL-2846 | AL-2846 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Bone metastases; Liver Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neurofibroma; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1 | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| S-49076 | S-49076 | Phase 2 Clinical | Servier | Glioblastoma; Carcinoma, Non-Small-Cell Lung | Details |
| ABN-401 | ABN-401; KDDF-201603-08 | Phase 2 Clinical | Abion Inc | Solid tumours | Details |
| Sym-015 | Sym-015 | Phase 2 Clinical | Symphogen | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SPH3348 | SPH-3348 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours | Details |
| RC-108 | RC-108; RC108 | Phase 1 Clinical | RemeGen Co Ltd | Solid tumours | Details |
| Altiratinib | DP-5164; DCC-2701; DCC-22701; T-678746713 | Phase 1 Clinical | Deciphera | Solid tumours; Neoplasms | Details |
| JNJ-38877618 | OMO-1; JNJ-38877618 | Phase 2 Clinical | Johnson & Johnson | Neoplasms | Details |
| SHR-A1403 | SHR-A1403 | Phase 1 Clinical | Solid tumours | Details | |
| Boxitinib Hydrochloride | Phase 1 Clinical | Hec Pharm Co Ltd | Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms | Details | |
| CM-118 | CM-118 | Phase 1 Clinical | Xcovery | Carcinoma, Non-Small-Cell Lung | Details |
| GST-HG161 | GST-HG161 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| AMG-337 | AMG-337 | Phase 2 Clinical | Amgen Inc | Solid tumours; Stomach Neoplasms; Sarcoma, Clear Cell; Esophageal adenocarcinoma | Details |
| BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305 | Phase 3 Clinical | Mirati Therapeutics | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
| Recombinant plasmid-hepatocyte growth factor | Pudk-HGF | Phase 3 Clinical | Academy Of Military Medical Sciences, Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd | Ischemia; Peripheral Arterial Disease | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
| HLX-55 | HLX-55; KTN-0216 | Phase 1 Clinical | Kolltan | Solid tumours | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Neoplasms | Details | |
| Refanalin | ANG-3777; BB-3; SNV-003 | Phase 3 Clinical | Vifor Pharma Ag, Angion Biomedica | Pneumonia; Myocardial Infarction; Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Delayed Graft Function | Details |
| Elzovantinib | TPX-0022 | Phase 1 Clinical | Turning Point Therapeutics Inc | Solid tumours | Details |
| Anti-cMet SIMPLE Antibody | ARGX-111 | Phase 1 Clinical | Argenx Se | Neoplasms | Details |
| c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | Phase 1 Clinical | The Second Hospital Of Nanjing Medical University | Carcinoma, Hepatocellular | Details | |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| Ningetinib Tosylate | CT-053; CT-053-PTSA | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| LM-061 | LM-061 | Phase 2 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Congenital Hyperinsulinism; Solid tumours | Details |
| CKD-702 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung | Details | |
| Bozitinib | CBT-101; CBI-3103; PLB-1001; APL-101 | Phase 2 Clinical | Beijing Purunao Biotechnology Co Ltd, Crown Bioscience, Cbt, Heng Kang | Solid tumours; Kidney Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Ganglioglioma; Brain Neoplasms; Lung Neoplasms; Glioma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| HS-10241 | HS-10241 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Liver Neoplasms; Solid tumours; Carcinoma; Stomach Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Telisotuzumab vedotin | ABBV-399; ABT-399 | Phase 3 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| XL-092 | XL-092 | Phase 1 Clinical | Exelixis | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms | Details |
| REGN-5093 | REGN-5093 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| REGN-5093-M114 | METxMET-M114; REGN5093-M114 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| NDX-1017 | NDX-1017; ATH-1017 | Phase 2 Clinical | M3 Biotechnology | Alzheimer Disease; Lewy Body Disease | Details |
| Bafisontamab | EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Carcinoid Tumor; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
